Evidence map›Paper›PMID 29923986›Full record

SynthesisMedicine2018

Serelaxin, recombinant human relaxin-2, for heart failure patients: A systematic review and meta-analysis.

Ling Yu, Lijuan Cao, Jing Sun, Zhongyi Li, Fengzhen Yao, Yabin Zhou

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ling YuHeilongjiang University of Traditional Chinese Medicine Second Department of Cardiovascular, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang Province Department of Obstetrics and Gynecology, The First Clinical Medical College of Jinan University, Guangzhou, Guangdong Province, China.
Lijuan Cao
Jing Sun
Zhongyi Li
Fengzhen Yao
Yabin Zhou
Heilongjiang University · CNFirst Affiliated Hospital of Heilongjiang University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSerelaxin, recombinant human relaxin-2, is a hormone with vasodilatory and end-organ protective effects. Recently, it has been licensed to treat acute decompensated heart failure. Here, a systematic review and meta-analysis on randomized controlled trials (RCTs) was performed to assess the effect of serelaxin on mortality and dyspnea improvement in patients with heart failure.

methodsRCTs comparing serelaxin treatment to other heart failure treatments were searched in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. The main endpoints were mortality and dyspnea improvement. Pooled data were assessed by using a random effects model.

resultsA total of 451 studies were identified, of which 8 studies (8477 participants) were eligible and included in our analysis. Compared with other heart failure treatment group, serelaxin group had no effect on 30-day, 60-day, and 180-day mortality (OR, 0.79; 95% CI, 0.65-0.96). Compared with control group, there was no effect on dyspnea improvement.

conclusionSerelaxin treatment is irrelevant with the mortality, and it cannot improve dyspnea of heart failure patients.

Indexed as

Acute DiseaseCardiotonic AgentsHeart FailureHumansRandomized Controlled Trials as TopicRecombinant ProteinsRelaxinTreatment OutcomeVasodilator AgentsCardiotonic AgentsRecombinant ProteinsRelaxinserelaxin protein, humanVasodilator Agents

Identifiers

PMID29923986
PMCPMC6023957
OpenAlexW2921315690

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.